Nov 2, 4:17 PM ET
Intuitive Surgical's board approved expanding its size from 10 to 11 members and appointed Aaron Martin, President of Insurance at Humana, to fill the new seat, effective January 1, 2027. Martin will not sit on any board committees at the start, and the board has determined he is independent under Nasdaq and SEC rules.
- Board size increases from 10 to 11 members; Martin's appointment is effective January 1, 2027.
- Martin will receive a prorated annual cash retainer of $70,000 and an initial restricted stock unit grant with a target value of $93,333.
- Before Humana, Martin was Vice President of Healthcare at Amazon and Executive Vice President and Chief Digital Officer at Providence St. Joseph Health.
Read the filing on SEC.gov ↗
Oct 20, 4:05 PM ET
Intuitive reported third-quarter 2026 revenue of $3.05 billion, up 22% from $2.51 billion a year earlier, with da Vinci procedures up about 14% and Ion procedures up about 31%. GAAP net income fell to $523 million, or $1.49 per diluted share, from $704 million, or $1.95, after a $450 million charge for an antitrust class action settlement, while non-GAAP earnings rose to $3.00 per diluted share from $2.40. The settlement still needs Court approval, and the company gave 2026 outlook ranges for da Vinci procedure growth, non-GAAP gross margin and non-GAAP operating expense growth.
- Revenue of $3.05 billion rose 22%; instruments and accessories were $1.80 billion and systems were $769 million.
- A $450 million pre-tax charge for the antitrust class action settlement cut GAAP EPS by $0.99; the settlement remains subject to preliminary and final Court approval.
- The company repurchased 7.8 million shares for $2.94 billion in the quarter and ended September 30, 2026 with $6.80 billion in cash and investments, down $1.83 billion.
- 2026 outlook: da Vinci procedure growth of 14% to 15%, non-GAAP gross margin of 68.7% to 69.3%, and non-GAAP operating expense growth of 11% to 13%.
Read the filing on SEC.gov ↗
Jul 16, 4:05 PM ET
Intuitive reported second-quarter 2026 revenue of $2.89 billion, up 19% from a year earlier, and GAAP net income of $818 million, or $2.29 per diluted share, compared with $658 million, or $1.81, in the second quarter of 2025. The company also gave full-year 2026 outlook ranges for da Vinci procedure growth and non-GAAP gross profit margin, and warned that additional tariffs could have a material effect on results.
- Revenue was $2.89 billion, up from $2.44 billion; instruments and accessories revenue rose 18% to $1.73 billion.
- Non-GAAP net income per diluted share was $2.80, compared with $2.19 in the second quarter of 2025.
- Results included a $28 million, or $0.08 per diluted share, benefit from IEEPA tariff refunds for prior periods.
- 2026 outlook: da Vinci procedure growth of 13.5% to 15.5%, with the company expecting to be closer to the midpoint; non-GAAP gross margin of 68.0% to 69.0%.
Read the filing on SEC.gov ↗
May 28, 4:35 PM ET
Intuitive said Taylor Patton, Global Senior Vice President of its endoluminal business, will become Chief Commercial and Marketing Officer effective July 1, 2026, succeeding Henry Charlton. Charlton will move to Senior Vice President of Global Business Operations on the same date. The filing does not include any financial figures, so the change is a leadership transition with no stated effect on results.
- Taylor Patton succeeds Henry Charlton as Chief Commercial and Marketing Officer, effective July 1, 2026
- Patton has spent nearly two decades with Intuitive and led the worldwide launch and growth of the Ion platform
- Charlton, with the company since 2003, becomes Senior Vice President of Global Business Operations
- The announcement was made in a press release dated May 28, 2026 (Exhibit 99.1)
Read the filing on SEC.gov ↗
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.